Mangalam Drugs & Organics Ltd. (MANGALAM) AI Stock Analysis

• Market Cap: ₹1.16B
• Dividend Yield: N/A
• Average Volume (3M): 6.94K
• Price to Earnings (P/E): 19.8
• Beta (1Y): 1.15
• Revenue Growth: -16.39%
• EPS Growth: -409.96%
• Country: IN
• Employees: 432
• Sector: Basic Materials
• Sector Strength: 60
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -8.72
• Shares Outstanding: 15,828,248
• 10 Day Avg. Volume: 2,813
• 30 Day Avg. Volume: 6,942
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹87.00
• Price Target Upside: 18.84% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 58 Neutral
• Price Target: ₹87.00 ▲(18.84% Upside)

Mangalam Drugs & Organics Ltd. has a mixed financial performance with challenges in revenue growth and profitability. Technical indicators suggest a neutral to slightly positive trend, while valuation metrics indicate moderate pricing. The absence of earnings call data and corporate events limits additional insights. The company needs to focus on improving profitability and cash flow stability to enhance its overall financial health.

Mangalam Drugs & Organics Ltd. Business Overview & Revenue Model

Company Description

Mangalam Drugs & Organics Ltd. (MANGALAM) is an Indian pharmaceutical company engaged in the manufacturing and distribution of Active Pharmaceutical Ingredients (APIs) and intermediates. The company primarily serves the pharmaceutical industry by supplying essential APIs used in the formulation of various drugs. With a focus on quality and innovation, Mangalam Drugs & Organics Ltd. plays a crucial role in the healthcare sector by contributing to the production of life-saving medications.

How the Company Makes Money

Mangalam Drugs & Organics Ltd. generates revenue primarily through the production and sale of Active Pharmaceutical Ingredients (APIs) and pharmaceutical intermediates. The company's key revenue streams include the sale of these products to pharmaceutical companies who use them to manufacture finished dosage forms of medications. Mangalam Drugs & Organics Ltd. may also engage in partnerships or contracts with pharmaceutical firms for the supply of specific APIs. Additionally, the company might earn from any research and development activities that lead to the creation of proprietary or specialized APIs, although specific partnership details or R&D revenue contributions are not available.

Mangalam Drugs & Organics Ltd. Financial Statement Overview

Summary

Mangalam Drugs & Organics Ltd. reflects a mixed financial performance with challenges in sustaining revenue growth and profitability. The balance sheet displays an adequate financial position with manageable debt levels, while cash flow management reveals fluctuations, particularly in free cash flow generation. The company needs to address profitability and cash flow stability to improve its financial health.

Income Statement

Mangalam Drugs & Organics Ltd. shows fluctuating revenue and profit margins. The most recent year indicates a decline in total revenue and net income, impacting the net profit margin negatively. EBIT and EBITDA margins have also contracted, reflecting challenges in maintaining profitability. Despite a prior trend of increasing revenue, the recent performance suggests instability in revenue growth and profitability.

Balance Sheet

The company's debt-to-equity ratio and equity ratio indicate a balanced financial position with manageable leverage. A consistent stockholders' equity and adequate asset management demonstrate financial stability. However, the increase in total debt over recent years suggests potential risk if revenue declines persist.

Cash Flow

Operating cash flow has shown improvement although free cash flow remains inconsistent. The operating cash flow to net income ratio indicates strong cash generation relative to net income, but negative free cash flow in several periods signals potential challenges in investing activities and capital expenditure management.

Breakdown	Mar 2025	Mar 2024	Mar 2023	Mar 2021	Mar 2022
Income Statement
Total Revenue	3.18B	3.67B	3.70B	3.80B	4.47B
Gross Profit	1.50B	188.12M	287.77M	976.69M	546.89M
EBITDA	358.23M	139.86M	259.54M	550.15M	451.84M
Net Income	67.21M	-90.72M	12.70M	279.71M	196.57M
Balance Sheet
Total Assets	3.66B	3.34B	3.60B	2.64B	3.28B
Cash, Cash Equivalents and Short-Term Investments	25.89M	11.87M	26.88M	5.92M	19.55M
Total Debt	962.30M	1.07B	885.47M	697.06M	879.04M
Total Liabilities	2.17B	1.98B	2.08B	1.33B	1.78B
Stockholders Equity	1.49B	1.36B	1.52B	1.31B	1.51B
Cash Flow
Free Cash Flow	223.93M	-79.20M	116.09M	-38.86M	-19.60M
Operating Cash Flow	425.94M	39.13M	395.23M	275.50M	257.09M
Investing Cash Flow	-194.72M	-118.27M	-221.72M	-312.85M	-273.26M
Financing Cash Flow	-217.12M	52.27M	-166.17M	26.98M	29.79M

Mangalam Drugs & Organics Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 73.21
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:MANGALAM, the sentiment is Negative. The current price of 73.21 is below the 20-day moving average (MA) of 85.81, below the 50-day MA of 84.21, and below the 200-day MA of 94.13, indicating a bearish trend. The MACD of -2.37 indicates Positive momentum. The RSI at 31.43 is Neutral, neither overbought nor oversold. The STOCH value of 6.07 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:MANGALAM.

Mangalam Drugs & Organics Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GANESHBE	69 Neutral	₹6.98B	17.58		―	-13.61%	-38.42%
BHAGERIA	64 Neutral	₹7.73B	16.90		0.86%	25.56%	92.57%
HPAL	61 Neutral	₹4.22B	25.12		0.65%	8.99%	-22.45%
KHAICHEM	60 Neutral	₹10.45B	26.43		0.41%	64.35%	―
MANGALAM	58 Neutral	₹1.16B	19.78		―	-16.39%	-409.96%
MANORG	57 Neutral	₹4.39B	19.01		―	11.14%	308.52%
Sector *	44 Neutral	AU$1.54B	-7.28	-26.52%	4.40%	-3.13%	-36.41%

Mangalam Drugs & Organics Ltd. Corporate Events

Mangalam Drugs Reports Quarterly Loss Amid Financial Challenges

Mangalam Drugs & Organics Ltd. announced the approval of its un-audited financial results for the quarter ending June 30, 2025. The company reported a net loss of Rs. 1,372.80 lakhs for the quarter, compared to a profit in the previous quarter, indicating a challenging financial period. The results were reviewed by statutory auditors who did not express any modified opinions. This financial performance may impact the company’s market positioning and stakeholder confidence.

Mangalam Drugs Reports Q1 Financial Results with Notable Loss

Mangalam Drugs & Organics Ltd. announced the approval of its unaudited financial results for the quarter ended June 30, 2025, during a board meeting held on August 7, 2025. The company reported a net loss of INR 1,372.80 lakhs for the quarter, reflecting a challenging financial period compared to the previous year. Despite the loss, the auditors did not express any modified opinions, indicating compliance with financial reporting standards. The announcement may impact stakeholders’ perception of the company’s financial health and market positioning.